Cargando…
Consistent Dosing Through the Salmeterol–Fluticasone Propionate Easyhaler for the Management of Asthma and Chronic Obstructive Pulmonary Disease: Robustness Analysis Across the Easyhaler Lifetime
Background: Easyhaler (registered trademark by Orion Corporation) is a multidose dry powder inhaler (DPI) for the treatment of asthma and chronic obstructive pulmonary disease (COPD), designed to be simple and easy to use. Salmeterol–fluticasone propionate (S-F) Easyhaler (50/250 and 50/500 μg per d...
Autores principales: | Turpeinen, Anni, Eriksson, Patrik, Happonen, Anita, Husman-Piirainen, Johanna, Haikarainen, Jussi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219197/ https://www.ncbi.nlm.nih.gov/pubmed/32960127 http://dx.doi.org/10.1089/jamp.2020.1592 |
Ejemplares similares
-
In Vitro Flow Rate Dependency of Delivered Dose and Fine Particle Dose of Salmeterol/Fluticasone Propionate Easyhaler and Seretide Diskus with Patient Flow Rates Collected in a Randomized Controlled Trial
por: Jõgi, Rain, et al.
Publicado: (2019) -
Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects
por: Kirjavainen, Merja, et al.
Publicado: (2018) -
Dose uniformity of budesonide Easyhaler® under simulated real-life conditions and with low inspiration flow rates
por: Haikarainen, Jussi, et al.
Publicado: (2017) -
Effectiveness and Treatment Compliance of Salmeterol–Fluticasone Easyhaler(®) Among Patients with Asthma, COPD, or Asthma–COPD Overlap Syndrome: Real-World Study Findings
por: Tamási, Lilla, et al.
Publicado: (2022) -
A non-interventional switch study in adult patients with asthma or COPD on clinical effectiveness of salmeterol/fluticasone Easyhaler(®) in routine clinical practice
por: Vinge, Ines, et al.
Publicado: (2021)